Implant Poised to Transform Macular Degeneration Treatment Implant Poised to Transform Macular Degeneration Treatment
A system that delivers ranibizumab without injections could be a turning point for patients with neovascular age-related macular degeneration, results from the highly anticipated LADDER trial show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Reminder: Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 2 August 2018, featuring data from the Phase 2 LADDER study of the Port Delivery System (RPDS) with Lucentis to be presented at the American Society of Retina Specialists (ASRS) annual meeting (20-25 July 2018) in Vancouver, Canada. (Source: Roche Investor Update)
Source: Roche Investor Update - July 27, 2018 Category: Pharmaceuticals Source Type: news
Laser, Anti-VEGF Therapy Similar for DME
(MedPage Today) -- Ranibizumab advantage at 2 years lost at 5 (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 25, 2018 Category: Primary Care Source Type: news
Genentech touts positive data for tiny, refillable eye implant
Roche‘s (OTC:RHHBY) Genentech touted positive top-line data today from a Phase II study of its Port Delivery System, an eye implant designed to administer a sustained dose of ranibizumab in patients with wet age-related macular degeneration.
The refillable device, which is roughly the size of a grain of rice, is intended to enable wet-AMD patients to go for months without needing to see an ophthalmologist for treatment. The current standard of care for wet-AMD involves monthly injections of anti-vascular endothelial growth factor therapy.
Get the full story at our sister site, Drug Delivery Business News.
T...
Source: Mass Device - July 25, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Genentech Roche Source Type: news
Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 2 August 2018, featuring data from the Phase 2 LADDER study of the Port Delivery System (RPDS) with Lucentis to be presented at the American Society of Retina Specialists (ASRS) annual meeting (20-25 July 2018) in Vancouver, Canada. (Source: Roche Investor Update)
Source: Roche Investor Update - July 11, 2018 Category: Pharmaceuticals Source Type: news
FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy
Roche today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis ® (ranibizumab injection) 0.3 mg prefilled syringe (PFS) as a new method of administering the medicine to treat all forms of diabetic retinopathy. (Source: Roche Investor Update)
Source: Roche Investor Update - March 22, 2018 Category: Pharmaceuticals Source Type: news
Genentech ’ s pre-filled syringe for diabetic retinopathy wins FDA nod
Roche‘s (OTC:RHHBY) Genentech announced today that the FDA approved its 0.3-mg pre-filled syringe as a new way to administer Lucentis to diabetic retinopathy patients.
The company’s drug is the only FDA-approved medicine indicated for the treatment of diabetic retinopathy. The 0.3-mg pre-filled syringe is the first device of its kind approved to deliver an anti-vascular endothelial growth factor agent to patients with diabetic retinopathy and diabetic macular edema.
Get the full story at our sister site, Drug Delivery Business News.
The post Genentech’s pre-filled syringe for diabetic retinopathy wins F...
Source: Mass Device - March 21, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat Genentech Roche Source Type: news
FDA Approves Genentech ’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
South San Francisco, CA -- March 21, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis (ranibizumab injection) 0.3 mg prefilled syringe... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 21, 2018 Category: Drugs & Pharmacology Source Type: news
893716 893716
Biomarkers from the anterior chamber of the eye help predict response to ranibizumab, which could spare patients repeated injections with an ineffective agent, a small trial suggested.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Biomarkers May Predict Rx Response in Diabetic Macular Edema Biomarkers May Predict Rx Response in Diabetic Macular Edema
Biomarkers from the anterior chamber of the eye help predict response to ranibizumab, which could spare patients repeated injections with an ineffective agent, a small trial suggested.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
